Jayvadan K Patel
Sankalchand Patel University, India
Biography
Abstract
Brain-targeted tempol/α-tocopherol -loaded poly-(lactide-co-glycolide) (PLGA) nanoparticles (NPs) conjugated with a transferrin antibody (OX 26) were developed using the supercritical fluid technique. These NPs may have utility in treating neurodegenerative diseases such as Parkinson’s disease. Central to these diseases is an increased production of reactive oxygen and nitrogen species which may take part in the development of these conditions. PLGA-b-PEG polymer conjugation was carried out using 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC)/N-hydroxysuccinimide (NHS) chemistry. PLGA-b-PEG NPs were developed using supercritical fluid technique. PLGA-PEG-maleimide NPs was prepared for antibody conjugation with tempol and α-tocopherol. To enhance the delivery of NPs to the central nervous system (CNS), the transferrin antibody was covalently attached to PLGA NPs by sulfhydryl-reactive groups with a PEG-maleimide cross linker. As proof of principle, the NPs were loaded with tempol and α-tocopherol, a free radical scavenger that has been shown to be protective against oxidative insults. The NPs showed a particle size suitable for blood brain barrier (BBB) permeation (particle size 50-80 nm) and demonstrated sustained drug release behaviour up to one week.